Arcus Biosciences Inc
Arcus Biosciences Inc
RCUS

Arcus Biosciences Inc (RCUS)

$25.343.81%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$23.66
Day's Range
$25.43
$16.74
52-Week Range
$49.1
1 month return31.7%
3 month return27.37%
1 year return9.44%
5 year return49.06%

Company Information

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1- 1.
OrganizationArcus Biosciences Inc
Employees236
CEO
IndustryHealth Technology

Analyst Recommendation

based on 17 analysts ratings

Buy
88%
Buy
11%
Hold
0%
Sell

Based on 17 Wall street analysts offering stock ratings for Arcus Biosciences Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 135.79%

Current

$25.34

Target

$59.75

Recommendation Trend

Based on 17 analyst

Current1M Ago3M Ago
Buy
15
15
15
Hold
2
2
2
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
1.8B
Book Value
11.89
Dividend Share
0.0
Dividend Yield
0.0
Earnings Share
0.71
PE Ratio
35.1831
Wall Street Target Price
64.6

Valuation

Trailing PE35.18
Forward PE0.0
Price/Sales (ttm)
4.68
Price/Book (mrq)
2.34
Enterprise Value
1.6B
Enterprise Value/Revenue
4.13
Enterprise Value/Ebitda
26.94

Technicals

Beta
0.85
50 Day MA
32.79
200 Day MA
34.43

Institutional Holdings

BlackRock Inc

5.76%

Bvf Inc

5.52%

Vanguard Group Inc

4.9%

Partner Fund Management LP

4.78%

FMR Inc

4.63%

EcoR1 Capital, LLC

4.55%

Discover more

Frequently Asked Questions

What is Arcus Biosciences Inc share price today?

Can Indians buy Arcus Biosciences Inc shares?

How can I buy Arcus Biosciences Inc shares from India?

Can Fractional shares of Arcus Biosciences Inc be purchased?

What are the documents required to start investing in Arcus Biosciences Inc stocks?

What are today’s High and Low prices of Arcus Biosciences Inc?

What are today’s traded volumes of Arcus Biosciences Inc?

What is today’s market capitalisation of Arcus Biosciences Inc?

What is the 52 Week High and Low Range of Arcus Biosciences Inc?

How much percentage Arcus Biosciences Inc is down from its 52 Week High?

How much percentage Arcus Biosciences Inc is up from its 52 Week low?

What are the historical returns of Arcus Biosciences Inc?

Who is the Chief Executive Officer (CEO) of Arcus Biosciences Inc?